Funded Research

Centre for Complex Disorders

Year

2003

Host institution

Vancouver Coastal Health

Research location

Vancouver General Hospital

Partner

Supervisor

CO-lEad

Serious mental disorders affect thinking, mood and behaviour. The consequences are suffering, impaired function in daily life and yearly costs estimated in Canada at tens of billions of dollars. Like diabetes, hypertension and asthma, mental disorders are complex disorders, meaning there is no single gene mutation, experience or environmental effect that can be held responsible. With a history of focused but isolated research strategies that have failed to address these complexities, present day treatments for schizophrenia and bipolar disorder are no more effective than those developed 50 years ago. There is also a lack of effective treatments for Alzheimer’s disease. The Centre for Complex Disorders (CCD) will seek integrative and transformative solutions to these health problems, with an initial focus on psychotic illnesses, such as bipolar disorder and some types of depression. These often begin in adolescence and cause those affected to lose contact with reality, and chronically become socially isolated and unable to work. The unit’s secondary focus will be complex disorders affecting memory in old age.

Leader:

Members:

  • Alasdair McMillan Barr, PhD
    The Scripps Research Institute
  • Thomas Ehmann, PhD
    Fraser Health
  • Alaa El-Husseini, PhD
    University of British Columbia
  • Elliot Goldner, MD
    University of British Columbia
  • Robert Holt, PhD
    BC Cancer Agency
  • Kerry Jang, PhD
    University of British Columbia
  • James Kennedy, MD, FRCPC
    University of Toronto
  • Alan Kingstone, PhD
    University of British Columbia
  • Lili Kopala, MD
    University of British Columbia
  • Donna Lang, PhD
    University of British Columbia
  • Tania Lecomte, PhD
    University of British Columbia
  • William MacEwan, MD, FRCPC
    University of British Columbia
  • Alex MacKay, MD
    University of British Columbia
  • Anthony Phillips, PhD
    University of British Columbia
  • Ric Procychyn, PhD
    University of British Columbia
  • Ronald Reid, PhD
    University of British Columbia
  • Geoffrey Smith, PhD
    University of British Columbia
  • Weihong Song, MD, PhD, University of British Columbia
  • Allen Thornton, PhD
    Simon Fraser University
  • Ivan Torres, PhD
    Simon Fraser University
  • Paul Waraich, PhD
    University of British Columbia
  • Richard Williams, MBBS, LMCC, FRCPC
    University of British Columbia

Serious mental disorders affect thinking, mood and behaviour. The consequences are suffering, impaired function in daily life and yearly costs estimated in Canada at tens of billions of dollars. Like diabetes, hypertension and asthma, mental disorders are complex disorders, meaning there is no single gene mutation, experience or environmental effect that can be held responsible. With a history of focused but isolated research strategies that have failed to address these complexities, present day treatments for schizophrenia and bipolar disorder are no more effective than those developed 50 years ago. There is also a lack of effective treatments for Alzheimer’s disease. The Centre for Complex Disorders (CCD) will seek integrative and transformative solutions to these health problems, with an initial focus on psychotic illnesses, such as bipolar disorder and some types of depression. These often begin in adolescence and cause those affected to lose contact with reality, and chronically become socially isolated and unable to work. The unit’s secondary focus will be complex disorders affecting memory in old age.

The CCD’s research program ranges from molecular genetic and protein research to clinical research and epidemiological and health services research aimed at developing evidence to inform health services policy development and planning. The interdisciplinary team will focus on four areas:

  • Clinical research to improve understanding of early life events and neurodevelopmental factors that predispose individuals to develop psychosis. This includes efforts to develop sensitive biological markers, such as changes in cognitive performance or altered patterns of brain activity that may be used to assess effectiveness of drug therapy and also help in earlier identification of promising new drugs. It also includes validating information in administrative databases on patients with schizophrenia to facilitate epidemiological and health services studies aimed at improving health services policy development and planning.
  • Understanding the fundamental cognitive disturbances in psychotic disorders (i.e. how disturbances in attention, learning and memory contribute to symptoms such as hallucinations, delusion and disturbed mood). The goal: to develop new information that will support the development of specific cognitive tests to predict onset of illness, relapse or progression to chronic states, and support clinical trials to determine the effects of drug treatment on improving cognitive function.
  • Genetic variation research to identify and develop tests for gene variants that influence and can be used to predict risk for psychosis and treatment response.
  • Neurobiology research to identify proteins involved in complex brain disorders, to understand how they interact and how interactions change when proteins are altered. The goal is to develop treatment strategies that will reverse protein abnormalities that contribute to psychotic disorders.

Award term completed September 2009.

Building research careers

Since 2001, we’ve supported over 3,000 BC health researchers to launch programs, drive innovations, and attract millions in new research investment.

View all funded research

Funded research